Editorial Hot Topic: Engineered Nucleases for Targeted Genome Modification (Guest Editors: Jean-Paul Concordet & Carine Giovannangeli)]

Jean-Paul      Concordet; Carine      Giovannangeli

doi:10.2174/156652311794520085

Rights & Permissions Print Cite

Current Gene Therapy

Title: Editorial Hot Topic: Engineered Nucleases for Targeted Genome Modification (Guest Editors: Jean-Paul Concordet & Carine Giovannangeli)]

Volume: 11 Issue: 1

Author(s): Jean-Paul Concordet and Carine Giovannangeli

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Concordet Jean-Paul and Giovannangeli Carine, Editorial Hot Topic: Engineered Nucleases for Targeted Genome Modification (Guest Editors: Jean-Paul Concordet & Carine Giovannangeli)], Current Gene Therapy 2011; 11 (1) . https://dx.doi.org/10.2174/156652311794520085

DOI https://dx.doi.org/10.2174/156652311794520085	Print ISSN 1566-5232
Publisher Name Bentham Science Publisher	Online ISSN 1875-5631

About this journal

Call for Papers in Thematic Issues

Submission closes on : ---

Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)

Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

Guest Editor(s): Hao Chi